The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2011

Filed:

Oct. 31, 2008
Applicants:

P. Jeffrey Conn, Brentwood, TN (US);

Craig W. Lindsley, Brentwood, TN (US);

Charles David Weaver, Franklin, TN (US);

Alice L. Rodriguez, Nashville, TN (US);

Colleen M. Niswender, Brentwood, TN (US);

Carrie K. Jones, Nashville, TN (US);

Richard Williams, Nashville, TN (US);

Inventors:

P. Jeffrey Conn, Brentwood, TN (US);

Craig W. Lindsley, Brentwood, TN (US);

Charles David Weaver, Franklin, TN (US);

Alice L. Rodriguez, Nashville, TN (US);

Colleen M. Niswender, Brentwood, TN (US);

Carrie K. Jones, Nashville, TN (US);

Richard Williams, Nashville, TN (US);

Assignee:

Vanderbilt University, Nashville, TN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/42 (2006.01); A01N 43/38 (2006.01); A61K 31/47 (2006.01); A61K 31/40 (2006.01); C07D 225/04 (2006.01); C07D 487/00 (2006.01); C07D 491/00 (2006.01); C07D 513/00 (2006.01); C07D 498/00 (2006.01); C07D 471/02 (2006.01); C07D 491/02 (2006.01); C07D 498/02 (2006.01); C07D 513/02 (2006.01); C07D 515/02 (2006.01); C07D 217/22 (2006.01); C07D 487/02 (2006.01); C07D 495/02 (2006.01); C07D 497/02 (2006.01); C07D 209/36 (2006.01);
U.S. Cl.
CPC ...
Abstract

In one aspect, the invention relates to bicyclic MGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.


Find Patent Forward Citations

Loading…